What is Zacks Research's Estimate for Exelixis Q4 Earnings?

Exelixis, Inc. (NASDAQ:EXEL - Free Report) - Zacks Research raised their Q4 2026 earnings estimates for shares of Exelixis in a research report issued to clients and investors on Tuesday, July 1st. Zacks Research analyst E. Bagri now expects that the biotechnology company will post earnings of $0.76 per share for the quarter, up from their previous forecast of $0.75. The consensus estimate for Exelixis' current full-year earnings is $2.04 per share. Zacks Research also issued estimates for Exelixis' Q2 2027 earnings at $0.74 EPS and FY2027 earnings at $2.95 EPS.

Several other brokerages have also commented on EXEL. Morgan Stanley restated an "overweight" rating and issued a $47.00 price objective (up from $40.00) on shares of Exelixis in a report on Wednesday, May 14th. Benchmark reiterated a "neutral" rating on shares of Exelixis in a report on Monday, June 23rd. Guggenheim set a $45.00 target price on shares of Exelixis and gave the stock a "buy" rating in a report on Thursday, May 15th. JMP Securities increased their target price on shares of Exelixis from $47.00 to $50.00 and gave the stock a "market outperform" rating in a report on Monday, June 23rd. Finally, UBS Group reiterated an "underperform" rating on shares of Exelixis in a report on Thursday, April 17th. Two research analysts have rated the stock with a sell rating, six have issued a hold rating and fourteen have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $43.56.

Exelixis Price Performance

Shares of EXEL stock traded down $1.99 during trading hours on Friday, hitting $44.16. The company had a trading volume of 4,708,008 shares, compared to its average volume of 2,505,400. The company's fifty day moving average is $41.99 and its 200 day moving average is $37.79. Exelixis has a fifty-two week low of $21.86 and a fifty-two week high of $49.62. The stock has a market capitalization of $12.04 billion, a PE ratio of 20.07, a price-to-earnings-growth ratio of 0.93 and a beta of 0.28.

Institutional Trading of Exelixis

Large investors have recently bought and sold shares of the business. Coppell Advisory Solutions LLC acquired a new stake in shares of Exelixis in the 4th quarter worth $25,000. Hemington Wealth Management lifted its stake in shares of Exelixis by 211.3% in the first quarter. Hemington Wealth Management now owns 769 shares of the biotechnology company's stock valued at $28,000 after purchasing an additional 522 shares during the period. Colonial Trust Co SC lifted its stake in shares of Exelixis by 616.9% in the fourth quarter. Colonial Trust Co SC now owns 889 shares of the biotechnology company's stock valued at $30,000 after purchasing an additional 765 shares during the period. Bartlett & CO. Wealth Management LLC acquired a new stake in shares of Exelixis in the first quarter valued at about $37,000. Finally, Costello Asset Management INC acquired a new stake in shares of Exelixis in the first quarter valued at about $39,000. Institutional investors and hedge funds own 85.27% of the company's stock.

Insider Transactions at Exelixis

In related news, Director Stelios Papadopoulos sold 36,508 shares of the stock in a transaction on Thursday, May 15th. The shares were sold at an average price of $44.35, for a total value of $1,619,129.80. Following the transaction, the director directly owned 1,279,416 shares of the company's stock, valued at $56,742,099.60. This trade represents a 2.77% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Christopher J. Senner sold 100,000 shares of the stock in a transaction on Friday, May 16th. The stock was sold at an average price of $46.00, for a total transaction of $4,600,000.00. Following the sale, the chief financial officer owned 967,842 shares of the company's stock, valued at approximately $44,520,732. This represents a 9.36% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 458,113 shares of company stock worth $21,024,817. Insiders own 2.85% of the company's stock.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.